Diabetes Kidney Disease Patient Care 
Cardiometabolic Health Congress
JUNE 24, 2024
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
Cardiometabolic Health Congress
JULY 25, 2024
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
Cardiometabolic Health Congress
AUGUST 8, 2024
Cardiometabolic risk encompasses a complex spectrum of interrelated conditions, including cardiovascular disease, type 2 diabetes, and metabolic syndrome. One promising strategy is the formation of creative partnerships between patients and their healthcare teams.
Cardiometabolic Health Congress
AUGUST 14, 2024
Themed “Decoding the Constellation of Cardiometabolic Health and Risk Factors,” this year’s congress will tackle the growing health threat posed by cardiometabolic diseases, affecting 47 million people in the US. Aronne, MD Expert Perspectives on Initiating and Maintaining Insulin Therapy in Type 2 Diabetes Patients Jay H.
Cardiometabolic Health Congress
NOVEMBER 8, 2023
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. The virtual, self-paced Foundations of Cardiometabolic Health Certificate Course is the first step to attaining the CCHP credential.
Cardiometabolic Health Congress
JULY 17, 2024
Staying informed about these cutting-edge developments is critical for providing exceptional patient care. Join us as we examine the landmark approvals that are revolutionizing patient outcomes. The first half of 2024 has ushered in a wave of transformative FDA approvals in cardiorenal metabolic health.
Dr. Malcolm Kendrick
DECEMBER 8, 2023
In addition, there are links to formal risk assessment in cardiovascular disease. With bonus hyperlinks to NICE’s guidelines on hypertension in chronic kidney disease and type I diabetes and type II diabetes and on and on. So much time doing work that has only the most tenuous link to patient care, and benefit.
Expert insights. Personalized for you.
52 
Let's personalize your content